SK2062003A3 - Pharmaceutical combination of angiotensin II antagonists and ACE inhibitors - Google Patents

Pharmaceutical combination of angiotensin II antagonists and ACE inhibitors Download PDF

Info

Publication number
SK2062003A3
SK2062003A3 SK206-2003A SK2062003A SK2062003A3 SK 2062003 A3 SK2062003 A3 SK 2062003A3 SK 2062003 A SK2062003 A SK 2062003A SK 2062003 A3 SK2062003 A3 SK 2062003A3
Authority
SK
Slovakia
Prior art keywords
ang
antagonist
ace inhibitor
ramipril
telmisartan
Prior art date
Application number
SK206-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Peter Bohm
Wolf Thomas Meinicke
Axel Riedel
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32234234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK2062003(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of SK2062003A3 publication Critical patent/SK2062003A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
SK206-2003A 2000-08-22 2001-08-16 Pharmaceutical combination of angiotensin II antagonists and ACE inhibitors SK2062003A3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0020691.2A GB0020691D0 (en) 2000-08-22 2000-08-22 Pharmaceutical combination
DE10108215A DE10108215A1 (de) 2000-08-22 2001-02-20 Pharmazeutische Kombination von Antagonisten von Angiotensin II und Hemmern von Angiotensin II konvertierendem Enzym
PCT/EP2001/009428 WO2002015891A2 (fr) 2000-08-22 2001-08-16 Combinaison pharmaceutique d'antagonistes de l'angiotensine ii et d'inhibiteurs de l'enzyme de conversion de l'angiotensine i
CA002372785A CA2372785A1 (fr) 2000-08-22 2002-02-21 Composition pharmaceutique contenant des antagonistes de l'angiotensine ii et des inhibiteurs de l'enzyme de conversion de l'angiotensine i
JP2002093288A JP2003238444A (ja) 2000-08-22 2002-02-21 アンギオテンシンｉｉ拮抗剤及びアンギオテンシンｉ変換酵素阻害剤の医薬組成物

Publications (1)

Publication Number Publication Date
SK2062003A3 true SK2062003A3 (en) 2003-08-05

Family

ID=32234234

Family Applications (1)

Application Number Title Priority Date Filing Date
SK206-2003A SK2062003A3 (en) 2000-08-22 2001-08-16 Pharmaceutical combination of angiotensin II antagonists and ACE inhibitors

Country Status (15)

Country Link
US (1) US20030171415A1 (fr)
EP (1) EP1313468A2 (fr)
JP (1) JP2003238444A (fr)
CN (1) CN1447691A (fr)
AU (1) AU2001295465B2 (fr)
BG (1) BG107558A (fr)
BR (1) BR0113321A (fr)
CA (2) CA2415788A1 (fr)
CZ (1) CZ2003534A3 (fr)
DE (1) DE10108215A1 (fr)
GB (1) GB0020691D0 (fr)
IL (1) IL153937A0 (fr)
NO (1) NO20030761L (fr)
SK (1) SK2062003A3 (fr)
WO (1) WO2002015891A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
DK1216038T3 (da) * 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
US20040157911A1 (en) * 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
US20040248968A1 (en) * 2002-02-20 2004-12-09 Boehringer Ingelheim International Gmbh Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
US9029363B2 (en) * 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
US20050004194A1 (en) * 2003-05-15 2005-01-06 Graves Kurt Chum Use of organic compounds
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
SE0302331D0 (sv) * 2003-08-29 2003-08-29 Astrazeneca Ab New use II
DE102004008804A1 (de) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
WO2005097109A1 (fr) * 2004-04-01 2005-10-20 Daniel Batlle Methodes pour obtenir un niveau d'expression d'ace2 protecteur
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
EP1723962A1 (fr) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Utilisation des inhibiteurs du système de rénine-angiotensine pour le traitement des lesions poumonaires.
US8080534B2 (en) * 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2009087116A1 (fr) * 2008-01-11 2009-07-16 Novartis Ag Utilisation de composés organiques
EP2684564A1 (fr) 2008-04-17 2014-01-15 Sanofi Utilisation de dronédarone dans un médicament utilisé pour prévenir un épisode cardiovasculaire menant à l' hospitalisation ou prévenir la fibrillation auriculaire
EP2116239A1 (fr) * 2008-04-29 2009-11-11 Sanofi-Aventis Procédé pour la gestion des risques associés à une augmentation de la créatinine sérique pendant un traitement à la dronédarone
CN101869710A (zh) * 2009-04-24 2010-10-27 北京奥萨医药研究中心有限公司 降压药物组合物
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
US20140170158A1 (en) * 2012-12-17 2014-06-19 The Johns Hopkins University Compositions and methods for treating or preventing lung diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821232A (en) * 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
EP0629408A1 (fr) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination d'inhibiteurs ACE et d'antagonistes AII
CZ313897A3 (cs) * 1995-04-07 1998-01-14 Novartis Ag Farmaceutické kompozice obsahující benazepril nebo benazeprilát a valsartan
JPH11508894A (ja) * 1995-06-30 1999-08-03 メルク エンド カンパニー インコーポレーテッド Ａｃｅ阻害剤とａｉｉ拮抗薬を用いる腎疾患の治療方法
JP2000513356A (ja) * 1996-06-24 2000-10-10 メルク エンド カンパニー インコーポレーテッド エナラプリルとロサルタンの組成物
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
DK1216038T3 (da) * 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser

Also Published As

Publication number Publication date
IL153937A0 (en) 2003-07-31
GB0020691D0 (en) 2000-10-11
WO2002015891A2 (fr) 2002-02-28
CN1447691A (zh) 2003-10-08
AU9546501A (en) 2002-03-04
DE10108215A1 (de) 2002-08-22
CA2415788A1 (fr) 2002-02-28
EP1313468A2 (fr) 2003-05-28
NO20030761D0 (no) 2003-02-18
CZ2003534A3 (cs) 2003-06-18
BR0113321A (pt) 2003-07-15
WO2002015891A3 (fr) 2002-06-13
BG107558A (bg) 2004-01-30
NO20030761L (no) 2003-02-18
CA2372785A1 (fr) 2003-08-21
AU2001295465B2 (en) 2007-12-13
JP2003238444A (ja) 2003-08-27
US20030171415A1 (en) 2003-09-11

Similar Documents

Publication Publication Date Title
SK2062003A3 (en) Pharmaceutical combination of angiotensin II antagonists and ACE inhibitors
AU2001295465A1 (en) Pharmaceutical combination of angiotensin II antagonists and ace inhibitors
TWI539950B (zh) 用於預防或治療貓之全身性疾病之血管緊張素ii受體拮抗劑
JPWO2003018061A1 (ja) キマーゼ阻害剤及びａｃｅ阻害剤を有効成分として含有する薬剤
AU716519B2 (en) Method of treating renal disease using an ace inhibitor and an A II antagonist
CA2537748C (fr) Utilisation de telmisartan pour la prevention de la cephalee vasculaire
US20080146639A1 (en) Pharmaceutical Combination of Angiotensin II Antagonists and Angiotensin I Converting Enzyme Inhibitors
US6329384B1 (en) Endothelin antagonist and renin-angiotensin system inhibitor as a combined preparation
See Angiotensin II receptor blockers for the treatment of hypertension
US20080114046A1 (en) Pharmaceutical Combination of Angiotensin II Antagonists and Angiotensin I Converting Enzyme Inhibitors
US20030158223A1 (en) Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
Israili et al. Direct renin inhibitors as antihypertensive agents
ZA200300556B (en) Pharmaceutical combination of angiotensin II antagonists and ace inhibitors.
Weir Angiotensin-II receptor antagonist: A new class of antihypertensive agents.
HK1104976A (en) Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
AU2007237280A1 (en) Pharmaceutical combination of Angiotensin II antagonists and Angiotensin I converting enzyme inhibitors
HK1057487A (en) Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
EP1382334A1 (fr) Utilisation d'un agent bloquant du récepteur AT1 de l'angiotensine II, seul ou combiné avec un thiazide ou l'angiotensine II dans le traitement des accidents vasculaires cérébraux
EP1478397A1 (fr) Combinaison pharmaceutique d'inhibiteurs d'enzymes de conversion d'antagonistes de l'angiotensine ii et de l'angiotensine i
KR20030069693A (ko) 안지오텐신 ⅱ 길항제 및 안지오텐신 ⅰ 전환효소억제제의 약제학적 배합물
WO2004098611A1 (fr) Stimulant
Andersen et al. Inhibition of the renin-angiotensin system, with particular reference to dual blockade treatment
Mbah Angiotensin II Receptor Antagonists: The Utility of the Therapeutic Agents in Clinical Practice
Veglio et al. Combinations of renin-angiotensin-aldosterone system antagonists: true advantages?
EA011655B1 (ru) Применение производного пиразола для получения лекарственных средств, подходящих для профилактики и лечения заболеваний почек

Legal Events

Date Code Title Description
FC9A Refused patent application